Abstract

Tenofovir disoproxil fumarate (TDF), is one of the approved drugs for chronic hepatitis B (CHB) management. Although not curative, it inhibits viral replication. It is generally considered safe but there is a strong risk of loss of bone mineral density and renal function.

AIM: To evaluate the renal and bone safety profile of TDF in CHB patients.

METHODOLOGY: This prospective observational study was started in January 2019 and the data is still being conducted in the Department of Gastroenterology & Hepatology, Jinnah Postgraduate Medical Centre (JPMC), Karachi, Pakistan. A total of 120 patients with CHB started on TDF therapy of either gender and having age more than 18 years to 60 years were recruited till date. Bone mineral density and renal functionas were assessed on the basis of pre and post Dual-Energy X-ray Absorptiometry (DEXA) scan & eGFR, respectively. Dexa score (T-Score) of less than -1.0 of left hip & spine and eGFR of less than 90ml/min was considered abnormal. Patients were assessed at the time of recruitement then after three and six months for comparison.